UNIGE document Scientific Article
previous document  unige:26321  next document
add to browser collection

Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study

Published in BMC Nephrology. 2012, vol. 13, no. 1, p. 132
Abstract ABSTRACT: BACKGROUND: Experimentally, erythropoietin (EPO) has nephroprotective as well as immunomodulatory properties when administered after ischemic renal injury. We tested the hypothesis that different doses of recombinant human EPO administered to patients after cardiac surgery would minimize kidney lesions and the systemic inflammatory response, thereby decreasing acute kidney injury (AKI) incidence. METHODS: In this double-blinded randomized control study, 80 patients admitted to the ICU post-cardiac surgery were randomized by computer to receive intravenously isotonic saline (n = 40) versus alpha-Epoetin (n = 40): either 40000 IU (n = 20) or 20000 IU (n = 20). The study lasted one year. The primary outcome was the change in urinary NGAL concentration from baseline and 48 h after EPO injection. Creatinine, cystatine C and urinary NGAL levels were measured on the day of randomization and 2--4 days after EPO injection. To assess acute inflammatory response, serum cytokines (IL6 and IL8) were measured at randomization and four days after r-HuEPO injection. Patients and care-takers were blinded for the assignment. RESULTS: No patient was excluded after randomization. Patient groups did not differ in terms of age, gender, comorbidities and renal function at randomization. The rate of AKI assessed by AKIN criteria was 22.5% in our population. EPO treatment did not significantly modify the difference in uNGAl between 48 hours and randomization compared to placebo [2.5 ng/ml (-17.3; 22.5) vs 0.7 ng/ml (-31.77; 25.15), p = 0.77] and the incidence of AKI was similar. Inflammatory cytokines levels were not influenced by EPO treatment. Mortality and hospital stays were similar between the groups and no adverse event was recorded. CONCLUSION: In this randomized-controlled trial, alpha-Epoetin administrated after cardiac surgery, although safe, demonstrated neither nephroprotective nor anti-inflammatory properties.Trial registration numberNCT00676234.
PMID: 23033926
Full text
Article (Published version) (558 Kb) - public document Free access
Research groups Groupe Eric Féraille (néphrologie) (29)
Groupe Pierre-Yves Martin (néphrologie) (30)
Groupe Pugin Jérôme (Soins intensifs) (587)
Insuffisance rénale chronique (941)
(ISO format)
DE SEIGNEUX MATTHEY, Sophie et al. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. In: BMC Nephrology, 2012, vol. 13, n° 1, p. 132. doi: 10.1186/1471-2369-13-132 https://archive-ouverte.unige.ch/unige:26321

485 hits



Deposited on : 2013-02-08

Export document
Format :
Citation style :